MDY Mdy Healthcare

RNS No 3015u
MEDISYS PLC
30 September 1999

                                Medisys PLC

                     Manufacturing Agreement Signed


Medisys PLC ("Medisys") announces that Futura Medical Technologies Inc.
("Futura"), its wholly owned subsidiary which owns the world-wide rights to
the Futura Safety Syringe, has signed a manufacturing and marketing agreement
with Acumen Enterprise Sdn. Bhd ("Acumen"), a subsidiary of Ulbon Berhad - a
public company listed on the Kuala Lumpur Stock Exchange.

Under the terms of the Agreement, Acumen will be granted rights for the
manufacture, marketing and sale of the Futura Safety Syringe in Malaysia and
Singapore. Acumen will pay an initial consideration of US$2 million for the
rights and will also pay a 10% royalty on all sales of the Futura Safety
Syringe in Malaysia and Singapore.  This agreement will secure a manufacturing
resource in South East Asia with Acumen committing to manufacture, and Futura
committing to purchase, 200 million units for the two year period following US
Food and Drug Administration ("FDA") approval of the product.

The Futura is an innovative safety syringe featuring a state of the art
automatic and passive retraction function - when the plunger is pressed down
fully the needle is automatically retracted into the syringe barrel.  Due to
the small number of components in the device, Medisys believes the Futura
Safety Syringe has a number of significant commercial advantages in terms of
ease and cost of manufacture.  Acumen is to manufacture the Futura Safety
Syringe in a facility compliant with FDA's Good Manufacturing Practice (cGMP)
in Singapore, which is already engaged in the manufacture of high volume FDA
approved medical devices.

Kurt Amundson, President and Chief Operating Officer of Medisys commented:
"Our manufacturing strategy for Futura is to have multiple manufacturing
sources to ensure that market demand can be satisfied.  This first step
supports our stated objective of establishing partnerships world-wide with
manufacturers who can meet the required regulatory standards, offer first
class operational and cost efficiencies, and facilitate a low risk rapid
market entry into the US.  This strategy allows us to leverage skills and
capabilities of third party manufacturers while optimising our capital
structure for shareholder value.  Working with our US based OEM, Futura is
currently on target to commence pilot production during the last calendar
quarter of 1999 and submit FDA 510(k) filing in the first calendar quarter of
2000."

Mr Yoshiharu Miyake, Group Managing Director of Ulbon said: "Acumen believes
that the Futura Safety Syringe is an extremely important product that can be
manufactured cost effectively in Malaysia and Singapore to compete with
conventional syringes on a world-wide basis and we are proud to be associated
with Futura and Medisys."


Medisys PLC       
Kurt Amundson, President & Chief Operating Officer       001 650 327 7900
Michael Barry, Chief Financial Officer                      07788 584 020

Square Mile Communications                                  0171 601 1000
Tim Jackaman



Notes to editors:

Medisys PLC

Medisys PLC develops, manufactures and markets diagnostic, medical and safety
products serving the rapid test and point of care medical market.  The Group
has two principal operating subsidiaries, Hypoguard and Futura Medical
Corporation, located in the UK and in the US respectively.  The diagnostic
division develops and supplies blood glucose monitoring systems for the
diabetic market.  Its future focus is on serving unmet medical needs through
the development of diagnostic products based on its own proprietary platform
technologies.

Futura and Needlestick Injury 

The Futura safety syringe has only three components, compared to the eleven in
a typical safety syringe, bringing considerable benefits in terms of
manufacturing expense and complexity.  The Futura technology has already won
PCT and US patents and functional prototypes have been produced. 

Needlestick injury and the associated risk of infectious disease transmission
is a major hazard to healthcare worker safety, with over 1 million needlestick
injuries being reported annually in the US alone.  Legislation in the US,
pioneered by California and Tennessee but now being introduced or drafted by
over half of US states, will make the use of safety needles mandatory.

The US market for disposable hypodermic syringes was estimated to be 6.6
billion units in 1997, with safety syringes accounting for around 5% of the
total.  Market research group Theta forecasts that safety syringe market share
will rise to 75% by 2001. 



END

MSCLMMLBLLBJMML

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jul 2023 bis Jul 2024